Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tatsuyoshi Ikenoue

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Scientific Reports|August 2, 2024
Prevalent and new use of common drugs for the incidence of community-acquired acute kidney injury: cohort and case-crossover studyMiho Kimachi, Tatsuyoshi Ikenoue, Shingo Fukuma
Oxford Medical Case Reports|May 31, 2021
Transfusion-dependent anaemia treatment using continuous erythropoietin receptor activator (epoetin β pegol) and roxadustat after darbepoetin treatment failure in low-risk myelodysplastic syndrome: a case reportTatsuyoshi Ikenoue, Yoshiyuki Furumatsu, Tetsuya Kitamura
Oxford Medical Case Reports|July 16, 2025
Over eight years of transfusion independence with continuous erythropoietin receptor activator and Roxadustat in transfusion-dependent low-risk myelodysplastic syndromeTatsuyoshi Ikenoue, Yoshiyuki Furumatsu, Tetsuya Kitamura
Journal of Medical Case Reports|October 20, 2017
Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case reportTatsuyoshi Ikenoue, Hiroshi Naito, Tetsuya Kitamura, et al.
Journal of Epidemiology and Community Health|September 30, 2019
Undiagnosed and untreated chronic kidney disease and its impact on renal outcomes in the Japanese middle-aged general populationYukari Yamada, Tatsuyoshi Ikenoue, Yoshiyuki Saito, et al.
JAMA Internal Medicine|October 8, 2020
Association of the National Health Guidance Intervention for Obesity and Cardiovascular Risks With Health Outcomes Among Japanese MenShingo Fukuma, Toshiaki Iizuka, Tatsuyoshi Ikenoue, et al.
BMJ Open|August 10, 2017
Impact of nutritional index on the association between phosphorus concentrations and mortality in haemodialysis patients: a cohort study from dialysis outcomes and practice pattern study in JapanShingo Fukuma, Tatsuyoshi Ikenoue, Tadao Akizawa, et al.
International Journal of Clinical Pharmacy|February 6, 2019
Factors associated with patient preferences towards deprescribing: a survey of adult patients on prescribed medicationsTakuya Aoki, Yosuke Yamamoto, Tatsuyoshi Ikenoue, et al.
Nephron|August 29, 2018
Increased Mortality Rate after Hospitalization Among Chronic Hemodialysis Patients: A Prospective Cohort StudySayaka Shimizu, Shingo Fukuma, Tatsuyoshi Ikenoue, et al.
Npj Aging|September 6, 2024
Monitoring reaction time to digital device in the very-old to detect early cognitive declineYukari Yamada, Tadahisa Okuda, Tomoe Uchida, et al.
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Scientific Reports|August 2, 2024
Prevalent and new use of common drugs for the incidence of community-acquired acute kidney injury: cohort and case-crossover studyMiho Kimachi, Tatsuyoshi Ikenoue, Shingo Fukuma
Oxford Medical Case Reports|May 31, 2021
Transfusion-dependent anaemia treatment using continuous erythropoietin receptor activator (epoetin β pegol) and roxadustat after darbepoetin treatment failure in low-risk myelodysplastic syndrome: a case reportTatsuyoshi Ikenoue, Yoshiyuki Furumatsu, Tetsuya Kitamura
Oxford Medical Case Reports|July 16, 2025
Over eight years of transfusion independence with continuous erythropoietin receptor activator and Roxadustat in transfusion-dependent low-risk myelodysplastic syndromeTatsuyoshi Ikenoue, Yoshiyuki Furumatsu, Tetsuya Kitamura
Journal of Medical Case Reports|October 20, 2017
Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case reportTatsuyoshi Ikenoue, Hiroshi Naito, Tetsuya Kitamura, et al.
Journal of Epidemiology and Community Health|September 30, 2019
Undiagnosed and untreated chronic kidney disease and its impact on renal outcomes in the Japanese middle-aged general populationYukari Yamada, Tatsuyoshi Ikenoue, Yoshiyuki Saito, et al.
JAMA Internal Medicine|October 8, 2020
Association of the National Health Guidance Intervention for Obesity and Cardiovascular Risks With Health Outcomes Among Japanese MenShingo Fukuma, Toshiaki Iizuka, Tatsuyoshi Ikenoue, et al.
BMJ Open|August 10, 2017
Impact of nutritional index on the association between phosphorus concentrations and mortality in haemodialysis patients: a cohort study from dialysis outcomes and practice pattern study in JapanShingo Fukuma, Tatsuyoshi Ikenoue, Tadao Akizawa, et al.
International Journal of Clinical Pharmacy|February 6, 2019
Factors associated with patient preferences towards deprescribing: a survey of adult patients on prescribed medicationsTakuya Aoki, Yosuke Yamamoto, Tatsuyoshi Ikenoue, et al.
Nephron|August 29, 2018
Increased Mortality Rate after Hospitalization Among Chronic Hemodialysis Patients: A Prospective Cohort StudySayaka Shimizu, Shingo Fukuma, Tatsuyoshi Ikenoue, et al.
Npj Aging|September 6, 2024
Monitoring reaction time to digital device in the very-old to detect early cognitive declineYukari Yamada, Tadahisa Okuda, Tomoe Uchida, et al.
Pageof 7